http://web.archive.org/web/20150501045944id_/http://www.dailymail.co.uk/news/article-2844877/Sight-saving-drug-blocked-red-tape-Bureaucratic-hurdles-prevent-patients-getting-treatment-save-NHS-100-million-year.html

some cash strapped @entity2 trusts have been telling consultants to switch to @entity4 eye specialists claim a cancer drug should be used on the @entity2 to prevent patients going blind – even though it is unlicensed			1
@entity4 is cheaper than the @entity2 - recommended treatment for age - related macular degeneration , the most common cause of vision loss in those aged over 50			1
according to the @entity14 of @entity15 , @entity4 could save the @entity16 £ 100million a year			1
some cash - strapped @entity2 trusts have been telling consultants to switch to the drug rather than use the recommended @entity20 , which is around ten times more expensive			1
but in doing so , doctors could fall foul of @entity24 rules , says the @entity14			1
it is calling for ‘ bureaucratic hurdles ’ to be removed by the @entity24 and the @entity26 ( @entity26 ) which would pave the way for use of the cheaper drug			2
@entity20 , which costs around £ 700 for an injection , is approved by @entity26 but @entity4 , costing an estimated £ 70 a shot , is not licensed for eye conditions			0
however , findings from clinical studies suggest @entity4 – used to treat bowel and breast cancer – is as effective and safe as @entity20			0
@entity37 , president of the @entity14 of @entity15 , is co-signatory to an editorial in the @entity39 , which appeals to the government to remove the hurdles preventing @entity4 ’s use			0
but she falls short of encouraging eye specialists to use the drug since the @entity24 ’s rules permit an unlicensed drug to be used only in the absence of a licensed medicine			1
hospital eye services are struggling to cope with demand posed by the need for patients to have regular injections at a ‘ time of austerity ’ , she said			0
‘ consequently patients may not be getting treatment when they need it			0
’ a study found switching from @entity20 to @entity4 could save @entity58 £ 102million a year , and the money saved could be invested in the eye services			2
the @entity61 said it did not intend to ask @entity26 to review the use of @entity4			0
a spokesman said : ‘ age - related macular degeneration is a very serious condition and there are already other licensed and @entity26 - recommended drugs available to treat this condition			0
’ according to the @entity14 of @entity15 , @entity4 could save the @entity16 £ 100million a year ( file picture )			2

unlicensed cancer drug should be used on the @entity2 to prevent blindness
@entity4 is ten times cheaper than the @entity2 - recommended treatment
drug would save cash strapped hospital trusts £ 100 million a year
some @entity2 trusts have been telling consultants to switch to the drug
medics could now fall foul of @entity24 rules

@entity2:NHS
@entity15:Ophthalmologists
@entity14:Royal College
@entity26:Nice
@entity37:Carrie MacEwen
@entity24:General Medical Council
@entity16:Health Service
@entity39:British Medical Journal
@entity4:Avastin
@entity20:Lucentis
@entity58:NHS England
@entity61:Department of Health